Subject(s)
Adenoviridae Infections , Encephalomyelitis, Autoimmune, Experimental , Encephalomyelitis , Humans , Animals , Adenoviridae , Encephalomyelitis/diagnosis , Autoantibodies , Adenoviridae Infections/complications , Adenoviridae Infections/diagnosis , Oligodendroglia , Glycoproteins , Myelin-Oligodendrocyte GlycoproteinABSTRACT
To describe the clinical course and prognosis of pediatric idiopathic intracranial hypertension (IIH) and examine the preferred management setting. IIH is characterized by increased intracranial pressure and is often associated with headaches and visual complaints. IIH is a preventable cause of vision loss in children. Hence, a rapid diagnosis followed by prompt treatment and follow-up is essential. However, standardization of the management of IIH in the pediatric population is not well established. Computerized medical charts of all 82 pediatric (< 18 years) patients diagnosed with IIH between 2007 and 2018 in the metropolitan area of Jerusalem were reviewed. Comparison was made between children followed in a multidisciplinary clinic in tertiary centers and those followed elsewhere. Detailed demographic and clinical data, as well as data regarding the follow-up setting and clinical course of the disease, were collected and analyzed. Recurrent IIH-related hospital returns were selected as a measurable marker for the uncontrolled disease. Recurrent IIH-related hospital return rate was significantly lower and occurred later among children followed by multidisciplinary teams compared to individual experts. Follow-up in multidisciplinary clinics improve the quality of life, and financial burden and may prevent permanent visual impairment in children with IIH.
Subject(s)
Intracranial Hypertension , Pseudotumor Cerebri , Humans , Child , Pseudotumor Cerebri/diagnosis , Pseudotumor Cerebri/therapy , Retrospective Studies , Quality of Life , Intracranial Hypertension/complications , Headache/complicationsABSTRACT
Pediatric stroke is considered an infrequent complication of COVID-19. Focal cerebral arteriopathy (FCA) is one of the most common causes of arterial ischemic stroke in a previously healthy child. The present report describes a toddler with FCA most likely induced by SARS-CoV-2 infection who showed significant clinical improvement that may be related to injection of intra-arterial nimodipine. To our knowledge, this is the first reported use of nimodipine in this setting.
